ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2624

Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population

John McDougall Jr.1, Charles G. Helmick2, S. Sam Lim3, Caroline Gordon4 and Elizabeth Ferucci5, 1Department of Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, 2National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, 3Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 4Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 5Alaska Native Medical Center, Anchorage, AK

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: diagnosis, Native Americans, primary care, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose

Systemic lupus erythematosus (SLE) is a complex disease that is traditionally diagnosed and managed by specialists, typically rheumatologists.  Higher SLE prevalence in racial/ethnic minorities such as American Indian/Alaska Native (AI/AN) people, often residing in areas with less access to rheumatologists, may necessitate diagnosis and management of SLE by primary care providers (PCP) in some cases. The purpose of this analysis was to identify areas of potential difference between PCP and specialist diagnosis and management of SLE in a population-based lupus registry of AI/AN people.

Methods

All individuals with SLE meeting our inclusion criteria were selected from the 2009 Indian Health Service lupus registry population. Inclusion in this analysis was limited to individuals with a final diagnosis of SLE made by a PCP or specialist (dermatologist, nephrologist or rheumatologist) and documented in the medical record.  Based on medical record abstraction, SLE classification criteria were validated for each individual. Testing for biologic markers of SLE and medication use at any time during the course of the disease were also abstracted.

Results

Of the 320 patients identified with a documented physician diagnosis of SLE, 71 had been diagnosed by a PCP.  SLE diagnosis by a specialist was associated with a higher median number of American College of Rheumatology (ACR) classification criteria (5 vs. 2), a higher percentage of patients meeting the definition of SLE by ACR criteria (79% vs. 22%), the Boston Weighted criteria (82% vs. 32%), and an abridged version of the Systemic Lupus International Collaborating Clinics (SLICC) criteria (83% vs. 35%) (p<0.001 for all comparisons). Additionally, specialist diagnosis was associated with an increased proportion with any testing for anti-double-stranded DNA antibody (93% vs 73%) and complement C3 and C4  (84% vs 52%) documented in the medical record (p<0.001 for all). Lastly, specialist diagnosis was associated with ever treatment with hydroxychloroquine (86% vs. 64%, p<0.001) as documented in the medical record at any time during their disease course.

Conclusion

Within the population studied, specialist diagnosis of SLE was associated with a higher number of SLE classification criteria met, a higher percentage of patients tested for biomarkers of disease, and a higher percentage of patients ever treated with hydroxychloroquine.


Disclosure:

J. McDougall Jr.,
None;

C. G. Helmick,
None;

S. S. Lim,
None;

C. Gordon,
None;

E. Ferucci,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-provider-specialty-on-the-diagnosis-and-management-of-systemic-lupus-erythematosus-in-the-american-indianalaska-native-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology